Cyclooxygenase‐2 Inhibitors Decrease Interleukin‐1β–Stimulated Prostaglandin E₂ and IL‐6 Production by Human Gingival Fibroblasts

Abstract

The results suggest that COX-2 inhibition may be useful in helping to control fibroblast production of IL-6 in patients with severe periodontitis.

Anti-inflammatory effect of α, β-Amyrin, a pentacyclic triterpene from Protium heptaphyllum in rat model of acute periodontitis

“…Detection limits for TNF-a were 10 pg/ml. fibroblast production, which is greatly influenced by bone resorbing cytokine IL-6 (Tipton et al, 2003). Several data in literature provide evidence that systemic therapy with COX-2 inibitors such as meloxicam and etoricoxib can retard the progression of experimentally induced periodontitis in rats during the initial experimental period and also retard bone resorption at a later stage (Holzhausen et al, 2005;Nassar et al, 2005).…”

Betacellulin in Chronic Periodontitis Patients With and Without Type 2 Diabetes Mellitus: An Immunohistochemical Study

“…There is enough evidence that PGE2 is an important mediator in the periodontal inflammation and bone destruction and also involved in tissue response regulation. Prostaglandin E2 plays an important role in periodontal inflammation by stimulating the suppression of lymphocyte production, decreasing the collagen synthesis by fibroblasts and influencing osteoclastic bone resorption [11,12].…”

Short-Term effect of COX-2 selective inhibitor as an adjunct for the treatment of periodontal disease: a clinical double-blind study in humans

“…The effects of NSAIDs on PGE 2 levels (2,13), gingival inflammation (17) and alveolar bone loss (16,18,19) have been widely examined in human, animal and in vitro experiments (6,20). In general, the results have shown beneficial effect the early phase of periodontal treatment, gingivitis and prevention of bone loss.…”

“…Higher levels of PGE 2 are associated with increased gingival inflammation and alveolar bone loss (1,3,6,7). Therefore, the purpose of this study was to evaluate a selective COX-2 inhibitor derived from phenylpropionic acid, Loxoprofen sodium, as an adjunct for periodontal disease treatment, using probing pocket depth (PD) to verify the inflammation reduction.…”